A preview of the emerging health companies profiled in the current issue of Start-Up. This month's profile group, "Respiratory Therapies: Moving Beyond Symptomatic Relief," features profiles of Pearl Therapeutics, Protectimmun and Pulmatrix. Plus these Start-Ups Across Health Care: 3WIN, Cianna Medical, GlySure and Promedior.
You may also be interested in...
Technology originally developed for one of the most sophisticated and advanced active implantable medical devices - cochlear implants - has been key to the development of 3WIN NV's deep brain stimulation device. The Flemish start-up's neurostimulator Synapse is designed to reduce collateral stimulation through the precise delivery of an electrical charge; as well as record the neural response to better target therapy for movement disorders.
Despite mounting evidence that controlling blood sugar levels in critical care patients reduces complications and shortens the length of ICU stay, clinicians have found total glucose control hard to achieve because of the frequent testing required to achieve tight management. GlySure Ltd. is developing a continuous intravascular glucose monitoring system based on optical fluorescence. The start-up says that its sensor, inserted into the patient through central venous or arterial lines, can be used to monitor glucose and other parameters continuously for long periods of time without clotting or other adverse effects.
Women diagnosed with early-stage breast cancer are increasingly choosing breast conservation therapy - lumpectomy followed by several weeks of daily whole breast irradiation - over mastectomy. But because the vast majority of cancer recurs at or near the lumpectomy cavity, there has been a shift toward more localized radiation. The Strut-Adjusted Volume Implant from Cianna Medical Inc. is a form of accelerated partial breast irradiation that combines tissue-sparing dosimetry with a single-entry device. Once inserted, the multi-catheter device expands to reveal numerous treatment pathways.